Clinical Trials Browser

Hodgkin Disease × Hematopoietic Stem Cell Mobilization × 90 days × Clear all

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease, Recurrence